About Reverie Labs
Reverie Labs focuses on improving the drug discovery process, particularly for cancer therapies, by using advanced computational tools. Their approach involves machine learning and cheminformatics to identify and optimize potential drug compounds quickly. This helps pharmaceutical companies and research institutions tackle complex challenges in medicinal chemistry and speeds up the transition from discovery to clinical trials. Unlike many competitors, Reverie Labs combines expertise from various scientific fields, allowing them to create effective tools for searching chemical space for new therapies. Their goal is to accelerate the development of innovative cancer treatments through strategic partnerships and advanced technology.
Cambridge, MassachusettsHeadquarters
2017Year Founded
$24.4MTotal Funding
SERIES_ACompany Stage
AI & Machine Learning, Biotechnology, HealthcareIndustries
11-50Employees
Risks
Increased competition from AI-driven drug discovery startups may dilute market share.
Over-reliance on partnerships with major pharma companies poses strategic risks.
Lack of a physical lab may limit experimental validation capabilities.
Differentiation
Reverie Labs uses machine learning to accelerate preclinical drug development.
The company focuses on developing innovative cancer therapies using computational tools.
Reverie Labs operates without traditional lab infrastructure, leveraging cloud computing.
Upsides
Reverie Labs raised $25 million to enhance its AI drug discovery platform.
Partnerships with Roche and Genentech boost Reverie's credibility and resources.
Growing interest in AI-driven drug discovery supports Reverie's market potential.
Funding
Total raised$24.43 M
Latest valuation$125.00 M
StageSERIES_A
SERIES A
1/31/2021$25
$125.00 MSEED
12/31/2017- Y CombinatorTop
N/A
$2.00 M